Search
Now showing items 1-4 of 4
Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group - ESOI Joint Paper.
(FRONTIERS MEDIA SA, 2022-01-10)
Response evaluation criteria in solid tumours (RECIST) v1.1 are currently the reference standard for evaluating efficacy of therapies in patients with solid tumours who are included in clinical trials, and they are widely ...
Lab-on-chip assay of tumour markers and human papilloma virus for cervical cancer detection at the point-of-care.
(NATURE PORTFOLIO, 2022-05-24)
Cervical cancer affects over half a million people worldwide each year, the majority of whom are in resource-limited settings where cytology screening is not available. As persistent human papilloma virus (HPV) infections ...
Diffusion-Weighted Magnetic Resonance Imaging in Ovarian Cancer: Exploiting Strengths and Understanding Limitations.
(MDPI, 2022-03-10)
Detection, characterization, staging, and response assessment are key steps in the imaging pathway of ovarian cancer. The most common type, high grade serous ovarian cancer, often presents late, so that accurate disease ...
Standardised lesion segmentation for imaging biomarker quantitation: a consensus recommendation from ESR and EORTC.
(SPRINGER, 2022-10-04)
BACKGROUND: Lesion/tissue segmentation on digital medical images enables biomarker extraction, image-guided therapy delivery, treatment response measurement, and training/validation for developing artificial intelligence ...